Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 17/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 13/20 | 1.00 |
| ▸ | ULK1 | O75385 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 0.87 |
| ▸ | CDK7 | P50613 | 2/20 | 0.87 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.87 |
| ▸ | AURKA | O14965 | 2/20 | 0.68 |
| ▸ | BRD4 | O60885 | 1/20 | 0.68 |
| ▸ | BCL6 | P41182 | 2/20 | 0.66 |
| ▸ | PLK4 | O00444 | 1/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.66 |
| ▸ | STK16 | O75716 | 1/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | PAK4 | O96013 | 1/20 | 0.66 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.66 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17544462 | 0.96 | PTK2 (0.91) | PTK2PTK2BULK1CDK1CDK7 | |
| SCHEMBL6212081 | 0.94 | PTK2 (0.88) | PTK2PTK2BULK1CDK1CDK7 | |
| SCHEMBL29382158 | 0.93 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CDK7 | |
| SCHEMBL31732817 | 0.93 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CDK7 | |
| SCHEMBL31060602 | 0.93 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CDK7 | |
| SCHEMBL5212404 | 0.93 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CDK7 | |
| SCHEMBL3155697 | 0.93 | PTK2 (0.87) | PTK2PTK2BULK1CDK1CDK7 | |
| SCHEMBL3159943 | 0.92 | PTK2 (0.85) | PTK2PTK2BULK1CDK1CDK7 | |
| SCHEMBL3156398 | 0.92 | PTK2 (0.85) | PTK2PTK2BULK1CDK1CDK7 | |
| SCHEMBL3159237 | 0.91 | PTK2 (0.84) | PTK2PTK2BULK1CDK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625121-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-20080182840-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-07-31 | — | — | US | claimed |
| US-20060281774-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2006-12-14 | — | — | US | claimed |
| US-7109335-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2006-09-19 | — | — | US | claimed |
| EP-1625121-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050009853-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-01-13 | — | — | US | claimed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | claimed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056807-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2023-04-27 | — | — | US | disclosed |
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2021163633-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050009853-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-01-13 | — | — | US | disclosed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056807-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182840-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | TYMS, TYMP, DPYD | PTK2 3522/4885PTK2B 2693/4885ULK1 3324/4885 |
| US-20230130766-A1 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | ULK1, ULK2, ULK3 | PTK2 613/4885PTK2B 388/4885ULK1 1/4885 |
| US-20050009853-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2 3522/4885PTK2B 2693/4885ULK1 3324/4885 |
| US-20060281774-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PTK2 3522/4885PTK2B 2693/4885ULK1 3324/4885 |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | PTK2 3004/4885PTK2B 1941/4885ULK1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.